Supplementary Figure Legends from The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Abstract

Supplementary Figure S5: Acalabrutinib demonstrates similar changes in proliferation and tumor burden in the CLL xenograft mouse model as ibrutinib.